Streptomycin
As of the edition of 20 October 2026, Streptomycin is a small molecule: marketed, first approved in 1951 (ES).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2001
- Kind
- Small molecule
- Brand name
- Sulfato De Estreptomicina Reig Jofre
- First approved
- 1 September 1951 (ES)
- Approvals on record
- 3 in 3 regions
- Holder of the most recent approval
- Sterimax; 3 holders in all
- Registered trials
- 6, 0 stopped early
- Disease areas
- Infections; Immune system; Lungs and airways; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 3 | 3 | 0 | 0 |
| Phase 2 | 1 | 1 | 0 | 0 |
| Phase 3 | 2 | 2 | 0 | 0 |
| All trials | 6 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Sterimax | Applicant | 2001 to now |
| Meiji Seika Pharma | Applicant |